Can pragmatic research, real-world data and digital technologies aid the development of psychedelic medicine?

Covid-19: Children’s mental health services in England are “nowhere near sufficient,” says commissioner

(2021) Elisabeth Mahase   BMJ-British Medical Journal

Selective serotonin reuptake inhibitor ‘discontinuation syndrome’ or withdrawal

(2020) Ivana Massabki et al.   BRITISH JOURNAL OF PSYCHIATRY

Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings

(2020) Matthias Forstmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Psychedelic Psychiatry’s Brave New World

(2020) David Nutt et al.   CELL

The Current Status of Psychedelics in Psychiatry

(2020) David Nutt et al.   JAMA Psychiatry

Digital Health Management During and Beyond the COVID-19 Pandemic: Opportunities, Barriers, and Recommendations

(2020) Becky Inkster et al.   JMIR Mental Health

Serotonin Receptor 2A Activation Promotes Evolutionarily Relevant Basal Progenitor Proliferation in the Developing Neocortex

(2020) Lei Xing et al.   NEURON

Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies

(2020) Kristoffer A. A. Andersen et al.   ACTA PSYCHIATRICA SCANDINAVICA

REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics

(2019) R. L. Carhart-Harris et al.   PHARMACOLOGICAL REVIEWS

The 2018 UK NHS Digital annual report on the Improving Access to Psychological Therapies programme: a brief commentary

(2019) Naomi Petra Moller et al.   BMC Psychiatry

Digital IAPT: the effectiveness & cost-effectiveness of internet-delivered interventions for depression and anxiety disorders in the Improving Access to Psychological Therapies programme: study protocol for a randomised control trial

(2018) Derek Richards et al.   BMC Psychiatry

The entropic brain - revisited

(2018) Robin L. Carhart-Harris   NEUROPHARMACOLOGY

Psychedelics Promote Structural and Functional Neural Plasticity

(2018) Calvin Ly et al.   Cell Reports

Serotonin, psychedelics and psychiatry

(2018) Robin L. Carhart-Harris   World Psychiatry

An exploratory study of experiences with conventional eating disorder treatment and ceremonial ayahuasca for the healing of eating disorders

(2018) Marika Renelli et al.   Eating and Weight Disorders-Studies on Anorexia Bulimia and Obesity

Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

(2018) Spencer L James et al.   LANCET

Open Dialogue: A Review of the Evidence

(2018) Abigail M. Freeman et al.   PSYCHIATRIC SERVICES

Predicting Responses to Psychedelics: A Prospective Study

(2018) Eline C. H. M. Haijen et al.   Frontiers in Pharmacology

Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors

(2017) Roland R Griffiths et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Psychiatry & the psychedelic drugs. Past, present & future

(2017) James J.H. Rucker et al.   NEUROPHARMACOLOGY

Single-Case Design, Analysis, and Quality Assessment for Intervention Research

(2017) Michele A. Lobo et al.   Journal of Neurologic Physical Therapy

The economic costs of mental disorders

(2016) Sebastian Trautmann et al.   EMBO REPORTS

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial

(2016) Roland R Griffiths et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial

(2016) Stephen Ross et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Our future: a Lancet commission on adolescent health and wellbeing

(2016) George C Patton et al.   LANCET

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population

(2015) Peter S Hendricks et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment

(2015) S Alboni et al.   MOLECULAR PSYCHIATRY

From the lab to the real world

(2015) G. Charness et al.   SCIENCE

Brain disorders? Precisely

(2015) T. R. Insel et al.   SCIENCE

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction

(2014) Matthew W Johnson et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Is there an excess of significant findings in published studies of psychotherapy for depression?

(2014) J. Flint et al.   PSYCHOLOGICAL MEDICINE

Pragmatic design in randomized controlled trials

(2014) M. Purgato et al.   PSYCHOLOGICAL MEDICINE

Childhood Adversities Increase the Risk of Psychosis: A Meta-analysis of Patient-Control, Prospective- and Cross-sectional Cohort Studies

(2012) Filippo Varese et al.   SCHIZOPHRENIA BULLETIN

The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?

(2011) Elizabeth O Lillie et al.   Personalized Medicine

Genetic Sensitivity to the Environment: The Case of the Serotonin Transporter Gene and Its Implications for Studying Complex Diseases and Traits

(2010) Avshalom Caspi et al.   AMERICAN JOURNAL OF PSYCHIATRY

Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations

(2010) Deborah R. Zucker et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Childhood and Adolescent Psychiatric Disorders as Predictors of Young Adult Disorders

(2009) William E. Copeland et al.   ARCHIVES OF GENERAL PSYCHIATRY